Clinical Trial Update: A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated the total systemic exposure bioequivalence of budesonide/glycopyrronium/formoterol delivered by a BGF MDI with a next-generation prope…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BGF MDI (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 1 | Status: COMPLETED | Results posted: 2025-04-29